지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 389 - 395 (7page)
이용수
초록· 키워드
오류제보하기
Background: Bone strength is impaired in patients with type 2 diabetes mellitus despite an increase in bone mineral density (BMD). Thiazolidinedione (TZD), a peroxisome proliferator activated receptor γ agonist, promotes adipogenesis, and suppresses osteoblastogenesis. Therefore, its use is associated with an increased risk of fracture. The aim of this study was to examine the in vitro and in vivo effects of lobeglitazone, a new TZD, on bone. Methods: MC3T3E1 and C3H10T1/2 cells were cultured in osteogenic medium and exposed to lobeglitazone (0.1 or 1 μM), rosiglitazone (0.4 μM), or pioglitazone (1 μM) for 10 to 14 days. Alkaline phosphatase (ALP) activity, Alizarin red staining, and osteoblast marker gene expression were analyzed. For in vivo experiments, 6-month-old C57BL/6 mice were treated with vehicle, one of two doses of lobeglitazone, rosiglitazone, or pioglitazone. BMD was assessed using a PIXImus2 instrument at the baseline and after 12 weeks of treatment. Results: As expected, in vitro experiments showed that ALP activity was suppressed and the mRNA expression of osteoblast marker genes RUNX2 (runt-related transcription factor 2) and osteocalcin was significantly attenuated after rosiglitazone treatment. By contrast, lobeglitazone at either dose did not inhibit these variables. Rosiglitazone-treated mice showed significantly accelerated bone loss for the whole bone and femur, but BMD did not differ significantly between the lobeglitazone-treated and vehicle-treated mice. Conclusion: These findings suggest that lobeglitazone has no detrimental effects on osteoblast biology and might not induce side effects in the skeletal system.
목차
등록된 정보가 없습니다.
참고문헌 (34)
참고문헌 신청
Overbeek JA / 2017 / Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi-database study / Clin Ther 39:759~770
Stolar MW / 2008 / Managing type 2 diabetes: going beyond glycemic control / J Manag Care Pharm 14(5 Suppl B):S2~S19
Tran L / 2015 / Pharmacologic treatment of type 2 diabetes: oral medications / Ann Pharmacother 49:540~556
Yki-Jarvinen H / 2004 / Thiazolidinediones / N Engl J Med 351:1106~1118
Grey A / 2013 / The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial / Eur J Endocrinol 170:255~262
Stolar MW / 2008 / Managing type 2 diabetes: going beyond glycemic control / J Manag Care Pharm 14(5 Suppl B):S2~S19
Tran L / 2015 / Pharmacologic treatment of type 2 diabetes: oral medications / Ann Pharmacother 49:540~556
Yki-Jarvinen H / 2004 / Thiazolidinediones / N Engl J Med 351:1106~1118
Grey A / 2013 / The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial / Eur J Endocrinol 170:255~262
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
Diabetes and Metabolism Journal
2017 .01
-
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2021 .01
-
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2022 .11
-
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
Journal of Korean Medical Science
2017 .01
-
Lobeglitazone attenuates allergic inflammatory response on asthmatic murine model induced by ovalbumin
한국실험동물학회 학술발표대회 논문집
2019 .01
-
Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
Endocrinology and Metabolism
2017 .01
-
Effects of the Lysine Methyltransferase Inhibitor AZ505 on Bone Metabolism
대한골대사학회지
2021 .11
-
Low bone mineral density in children and adolescents with cancer
Annals of Pediatirc Endocrinology & Metabolism
2020 .01
-
Effects of Advanced Glycation End Products on Differentiation and Function of Osteoblasts and Osteoclasts
Journal of Korean Medical Science
2021 .09
-
Bone microarchitecture and bone mineral density in Graves’ disease
Osteoporosis and Sarcopenia
2023 .06
-
Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
Endocrinology and Metabolism
2021 .08
-
Effects of teriparatide on bone in autochthonous transgenic model mice for diabetes mellitus (Akita mice)
Osteoporosis and Sarcopenia
2019 .01
-
Comparison of Bone Mineral Density and Markers of Bone Turnover in Osteoporotic Women after 6-Month Treatment with Alendronate or Bazedoxifene: A Randomized Controlled Trial
대한골대사학회지
2021 .01
-
Changes in Bone Metabolism in Young Castrated Male Rats
Yonsei Medical Journal
2016 .01
-
Impact of Artistic Gymnastics on Bone Formation Marker, Density and Geometry in Female Adolescents: ABCD-Growth Study
대한골대사학회지
2019 .01
-
Bone modeling, remodeling, and skeletal health in children and adolescents: mineral accrual, assessment and treatment
Annals of Pediatirc Endocrinology & Metabolism
2017 .01
-
Relationship between Serum Inflammatory Marker and Bone Mineral Density in Healthy Adults
대한골대사학회지
2016 .01
-
Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma
대한골대사학회지
2015 .01
-
Evaluation of bone mineral density and bone strength in autochthonous transgenic model mice for diabetes mellitus (Akita mice)
Osteoporosis and Sarcopenia
2015 .01
-
Relationship between Type 2 Diabetes Mellitus and Lumbar Bone Mineral Density in Postmenopausal Women
Asian Spine Journal
2021 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0